Vorapaxar

Vorapaxar

Vorapaxar (pronounced: vo-RA-pax-ar) is a medication used to reduce the risk of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease.

Etymology

The name Vorapaxar is derived from the chemical structure of the drug. The prefix "Vora-" is derived from the Latin word "vorax", meaning "devouring", and the suffix "-paxar" is an arbitrary suffix used to denote its classification as a protease-activated receptor antagonist.

Pharmacology

Vorapaxar is a protease-activated receptor-1 (PAR-1) antagonist. It works by inhibiting the action of thrombin, a protein involved in blood clotting, on PAR-1 receptors. This prevents platelet aggregation, reducing the risk of thrombotic cardiovascular events.

Related Terms

• Thrombin
• Protease-activated receptor-1
• Platelet aggregation
• Myocardial infarction
• Peripheral arterial disease

See Also

• Anticoagulant
• Antiplatelet drug
• Cardiovascular disease

External links

• Medical encyclopedia article on Vorapaxar
• Wikipedia's article - Vorapaxar

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski